Pharmacologic treatments of dementia (Q34779344)

4 August 2017

1 reference

title

Pharmacologic treatments of dementia (English)

1 reference

4 August 2017

1 reference

Lauren T Bonner

1

1 reference

PubMed ID

12171061

4 August 2017

Elaine R Peskind

series ordinal

2

1 reference

4 August 2017

1 May 2002

1 reference

Medical Clinics of North America

4 August 2017

1 reference

4 August 2017

86

1 reference

4 August 2017

3

1 reference

4 August 2017

657-674

1 reference

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Estimated prevalence of Alzheimer's disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A cholinergic connection between normal aging and senile dementia in the human hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Selective loss of central cholinergic neurons in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Neurotransmitter changes in early- and late-onset Alzheimer-type dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Nicotinic acetylcholine binding sites in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Clinical effects of choline in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Choline chloride treatment of memory deficits in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Effects of physostigmine and lecithin on memory in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Human Serial Learning: Enhancement with Arecholine and Choline Impairment with Scopolamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A new rating scale for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Rivastigmine. A review of its use in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Involvement of free radicals in dementia of the Alzheimer type: a hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Ginkgo biloba leaf extract: review of biological actions and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Development and validation of the geriatric evaluation by relatives rating instrument (GERRI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Tacrine efficacy in Lewy body dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2802%2900007-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(02)00007-X

1 reference

4 August 2017

1 reference

PubMed ID

12171061